The Desmoid Tumor Research Foundation is dedicated to spreading knowledge about desmoid tumors among clinicians and researchers.
We form partnerships with entities that specialize in creating authorized Continuing Medical Education (CME) credit courses for medical professionals, providing the opportunity and incentive to increase their understanding of this rare tumor type and its treatment.
These courses are available to medical oncologists, surgical oncologists, general surgeons, advanced practice clinicians, and other healthcare professionals involved in the care of patients with desmoid tumors to ensure the greatest potential impact on patient outcomes.
Current CME-certified programs on desmoid tumors:
Activity Release Date: May 30, 2025
Activity Expiration Date: June 29, 2026
Time to Complete Activity: 30 minutes
Activity Description
Desmoid tumors (DTs) are known for their aggressive and invasive nature, leading to significant morbidity and high recurrence rates. The variability in their presentation and clinical progression often complicates timely and accurate diagnosis, with misdiagnoses frequently causing delays in effective intervention. Historically, complex treatment pathways for DTs have caused uncertainty; however, recent evidence on the gamma-secretase inhibitor, nirogacestat, has shown substantial clinical benefit across patient subgroups, resulting in a remodeled guideline-recommended therapeutic framework for DTs. Is your practice equipped to utilize the latest data to implement patient-centric frameworks for managing these rare and aggressive soft-tissue malignancies?
Join PeerView Live during the 2025 SARC Semiannual Meeting (held before the 2025 ASCO Annual Meeting) to gain a more profound working knowledge for treating DTs in patients with progressive disease. This Seminars & Tumor Board format, in collaboration with The Desmoid Tumor Research Foundation and the Sarcoma Alliance for Research through Collaboration, will showcase expert panelists sharing cutting-edge strategies for implementing personalized frameworks in DTs and clinical applications for GSIs across patient subgroups. Register today to join us for this symposium and get started on improved outcomes for your patients with DTs!
Target Audience
This activity has been designed to meet the educational needs of oncologists, sarcoma specialists, and other clinicians involved in the management of desmoid tumors.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Summarize clinical characteristics, diagnostic protocols, current guideline recommendations, and recent safety and efficacy evidence on the use of gamma-secretase inhibitors for the management of desmoid tumors
- Select appropriate systemic treatment options for desmoid tumors that consider current clinical trial evidence, preferred regimens from practice guidelines, and patient-specific factors
- Integrate strategies to address practical aspects of care and improve patient adherence to modern systemic treatment options, including dosing/scheduling considerations, patient education and shared decision-making, care coordination, and adverse event management
Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty
Co-Chair/Planner
Prof. Patrick Schöffski, MPH
Head, Department of General Medical Oncology
Leuven Cancer Institute
Comprehensive Cancer Center
University Hospitals Leuven
Faculty of Medicine
Department of Oncology
Head, Research Unit Laboratory of Experimental Oncology
KU Leuven
Leuven, Belgium
Co-Chair/Planner
Breelyn A. Wilky, MD
Associate Professor and Director of Sarcoma Medical Oncology University of Colorado Cancer Center
Aurora, Colorado
Accreditation, Support, and Credit
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, The Desmoid Tumor Research Foundation, and Sarcoma Alliance for Research through Collaboration. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc.
Physicians
PVI, PeerView Institute for Medical Education, designates this live activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
CME credits expire June 29, 2026
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Copyright © 2000-2025, PeerView
Past CME-certified programs on desmoid tumors:
Creators:
Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders (NORD) and the Desmoid Tumor Research Foundation (DTRF)
Availability:
Program Expired: December 12, 2024
Description:
Desmoid tumors are challenging to manage due to the difficulty obtaining an accurate diagnosis and the scarcity of treatment options. Despite the benefits seen with tyrosine kinase inhibitors, there are no FDA-approved therapies yet for treatment of desmoid tumors. However, emerging therapies are showing clinical benefit and have the potential to improve the treatment armamentarium.
Join a panel of experts to discuss the best strategies to improve timely diagnoses of patients with desmoid tumors. Experts will review the recent shift away from extensive surgery to active surveillance and explore emerging treatments that have demonstrated promising results for patients with progressive disease. Panelists will also discuss the need for multidisciplinary review to determine if treatment is warranted and examine which patients are eligible for treatment with emerging options.
Learning Objectives:
- Apply relevant strategies to address timely diagnosis in patients with desmoid tumors
- Discuss patient selection for treatment based on safety and efficacy data
Topics of Interest:
- Impact of misdiagnoses on outcomes with desmoid tumors
- Practical strategies to improve diagnostic accuracy
- Treatment burden and patient quality of life
- Conventional treatment approaches
- Gamma secretase inhibitors
- Where do emerging agents fit in the timeline?
- Role of the multidisciplinary team in care
- Special considerations for adolescent and young adult (AYA) patients
- Counseling patients about clinical trials, resources, and patient organizations
Top Faculty/ KOLs:
Mrinal Gounder, MD
Associate Attending Professor
Sarcoma Oncologist & Early Phase Drug Development Specialist
Memorial Sloan Kettering Cancer Center
Richard F. Riedel, MD
Associate Professor of Medicine with Tenure
Associate Director, Duke Sarcoma Center
Duke Cancer Institute
Duke University
ACKNOWLEDGEMENT
This activity is supported by an independent educational grant from SpringWorks Therapeutics, Inc.
DATE OF LIVE ACTIVITY
This activity was released on December 12, 2023 and is valid for 12 months. Requests for credit must be made no later than December 12, 2024.
TARGET AUDIENCE
The educational design of this activity addresses the needs of sarcoma specialists, medical oncologists, and other members of the care team for desmoid tumors.
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETE
This activity should take approximately 1 hour to complete.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.
DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPS
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
| Name of Faculty or Presenter | Reported Financial Relationship |
Mrinal Gounder, MD Associate Attending Professor Sarcoma Oncologist & Early Phase Drug Development Specialist Memorial Sloan Kettering Cancer Center | Consulting Fee (e.g., Advisory Board): Ayala Therapeutics, Aadi Biosciences, Rain Oncology, Epizyme, Regeneron, Boehringer Engelheim, Bayer Contracted Research (Principal Investigators must provide information, even if received by the institution): Ayala Therapeutics, Aadi Biosciences, Bayer, Boehringer Ingelheim, Epizyme, Springworks, Rain Oncology |
Richard F. Riedel, MD Associate Professor of Medicine with Tenure Associate Director, Duke Sarcoma Center Duke Cancer Institute Duke University | Consulting Fee (e.g., Advisory Board): AADi, Adaptimmune, Blueprint, Boehringer Ingelheim, Daiichi-Sankyo, Deciphera, GlaxoSmithKline, NanoCarrier, SpringWorks Contracted Research (Principal Investigators must provide information, even if received by the institution): AADi, AROG, Ayala, BioAtla, Blueprint, Cogent, Daiichi-Sankyo, Deciphera, GlaxoSmithKline, InhibRx, NanoCarrier, Oncternal, PTC Therapeutics, SARC, SpringWorks, Tracon, Trillium |
Christina Kosyla Vignette Participant Desmoid Tumor Patient | Nothing to disclose |
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT INFORMATION
Physician Accreditation Support:
For information about the physician accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.
Creators:
PeerView & the DTRF (Made possible with support from SpringWorks Therapeutics)
Availability:
Expired November 26, 2024
Mediums:
The PeerView inQuiry presentation can be downloaded in MP3 format, and the entire program is available as a podcast via the PeerView channels on Apple Podcasts, Spotify, TuneIn, Google Podcasts, and Amazon Alexa. The podcasts and online media player are fully compatible with all mobile devices. Furthermore, all the slides are easily downloadable as a PowerPoint slide kit.
Description:
Until recently, ICD-10-CM codes for desmoid tumors (DTs) were broadly defined, creating a significant impediment to research efforts. Through a didactic expert-led discussion, get to know the new ICD-10-CM codes for desmoid tumors and learn how to navigate these codes more efficiently as a healthcare provider or researcher in this new question-based activity that lets you earn your CME credit as you go.
This educational program leverages microlearning through question-based segments to help clinicians better navigate the variable presentations of desmoid tumors and the new ICD-10-CM codes. Throughout the program, two leading experts address gaps and barriers that affect healthcare providers, patients, and researchers by offering practical guidance on current evidence-based diagnostic strategies, describing the new desmoid tumor–specific ICD-10-CM codes, and detailing the new codes’ implications for clinical practice, patient care, and research. In addition to these question-based segments, downloadable Practice Aids and additional resources for clinicians and patients are available.
Upon completion of this activity, participants should be better able to:
- Discuss the gaps and barriers in the diagnosis and treatment of desmoid tumors (DTs), including the prior lack of DT-specific ICD-10-CM codes
- Characterize the details of the new DT-specific ICD-10-CM codes, including the subcategories for tumor locations
- Implement best practices for integrating the new DT-specific ICD-10-CM codes in clinical and research settings
- Employ the latest recommendations for establishing an accurate diagnosis and assigning the correct ICD-10-CM codes to patients with DTs to guide further care decisions
Continue Exploring
Clinicians & Researchers Newsletter
Receive monthly updates about treatment advances, grant applications, clinical trials, CME opportunities, and more.
The Annual DTRF International Desmoid Tumor Research Workshop
DTRF Patient Meeting
Our Patient Meeting is a time to hear from clinicians, researchers, and desmoid patients and caregivers during our annual DTRF Together We Will Weekend.
